420 related articles for article (PubMed ID: 30447212)
1. Incidence of sarcoma in patients undergoing hysterectomy for benign indications: a population-based study.
Multinu F; Casarin J; Tortorella L; Huang Y; Weaver A; Angioni S; Melis GB; Mariani A; Stewart EA; Laughlin-Tommaso SK
Am J Obstet Gynecol; 2019 Feb; 220(2):179.e1-179.e10. PubMed ID: 30447212
[TBL] [Abstract][Full Text] [Related]
2. Practice Patterns and Complications of Benign Hysterectomy Following the FDA Statement Warning Against the Use of Power Morcellation.
Multinu F; Casarin J; Hanson KT; Angioni S; Mariani A; Habermann EB; Laughlin-Tommaso SK
JAMA Surg; 2018 Jun; 153(6):e180141. PubMed ID: 29641835
[TBL] [Abstract][Full Text] [Related]
3. Risk of Occult Uterine Sarcoma in Presumed Uterine Fibroids.
Cui RR; Wright JD
Clin Obstet Gynecol; 2016 Mar; 59(1):103-18. PubMed ID: 26645385
[TBL] [Abstract][Full Text] [Related]
4. Clinical Characteristics and Prognosis of Unexpected Uterine Sarcoma After Hysterectomy for Presumed Myoma With and Without Transvaginal Scalpel Morcellation.
Zhang J; Li T; Zhang J; Zhu L; Lang J; Leng J
Int J Gynecol Cancer; 2016 Mar; 26(3):456-63. PubMed ID: 26807642
[TBL] [Abstract][Full Text] [Related]
5. Does fibroids surgery by endoscopy or laparotomy represent a malignancy threat?
Mettler L; Abdusattarova K; Alkatout I
Minerva Ginecol; 2017 Dec; 69(6):517-525. PubMed ID: 28696085
[TBL] [Abstract][Full Text] [Related]
6. Prevalence, characteristics, and risk factors of occult uterine cancer in presumed benign hysterectomy.
Desai VB; Wright JD; Gross CP; Lin H; Boscoe FP; Hutchison LM; Schwartz PE; Xu X
Am J Obstet Gynecol; 2019 Jul; 221(1):39.e1-39.e14. PubMed ID: 30853364
[TBL] [Abstract][Full Text] [Related]
7. Occult Uterine Sarcoma and Leiomyosarcoma: Incidence of and Survival Associated With Morcellation.
Raine-Bennett T; Tucker LY; Zaritsky E; Littell RD; Palen T; Neugebauer R; Axtell A; Schultze PM; Kronbach DW; Embry-Schubert J; Sundang A; Bischoff K; Compton-Phillips AL; Lentz SE
Obstet Gynecol; 2016 Jan; 127(1):29-39. PubMed ID: 26646120
[TBL] [Abstract][Full Text] [Related]
8. Risk of Occult Uterine Sarcoma in Women Undergoing Hysterectomy for Benign Indications.
Kho KA; Lin K; Hechanova M; Richardson DL
Obstet Gynecol; 2016 Mar; 127(3):468-473. PubMed ID: 26855091
[TBL] [Abstract][Full Text] [Related]
9. Unexpected gynecologic malignancy diagnosed after hysterectomy performed for benign indications.
Mahnert N; Morgan D; Campbell D; Johnston C; As-Sanie S
Obstet Gynecol; 2015 Feb; 125(2):397-405. PubMed ID: 25569001
[TBL] [Abstract][Full Text] [Related]
10. Unsuspected Uterine Sarcoma in an Urban Hospital: Does Surgical Approach Matter?
DiNapoli MN; Truong MD; Halfon JK; Burke WM
J Minim Invasive Gynecol; 2018; 25(3):491-497. PubMed ID: 29061369
[TBL] [Abstract][Full Text] [Related]
11. Risk of morcellation of uterine leiomyosarcomas in laparoscopic supracervical hysterectomy and laparoscopic myomectomy, a retrospective trial including 4791 women.
Lieng M; Berner E; Busund B
J Minim Invasive Gynecol; 2015; 22(3):410-4. PubMed ID: 25460521
[TBL] [Abstract][Full Text] [Related]
12. A Multicentre Retrospective Review of Clinical Characteristics of Uterine Sarcoma.
Wais M; Tepperman E; Bernardini MQ; Gien LT; Jimenez W; Murji A
J Obstet Gynaecol Can; 2017 Aug; 39(8):652-658. PubMed ID: 28729098
[TBL] [Abstract][Full Text] [Related]
13. Incidence of Tissue Morcellation During Surgery for Uterine Sarcoma at a Canadian Academic Centre.
Chen I; Hopkins L; Firth B; Boucher J; Singh SS
J Obstet Gynaecol Can; 2015 May; 37(5):421-425. PubMed ID: 26168102
[TBL] [Abstract][Full Text] [Related]
14. The incidence of unexpected uterine malignancies in hysterectomies carried out for benign indications.
Ding Y; Han Y; Zhang S; Shi X
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4339-4345. PubMed ID: 36083311
[TBL] [Abstract][Full Text] [Related]
15. Incidence of Occult Uterine Malignancy Following Vaginal Hysterectomy With Morcellation.
Wasson M; Magtibay P; Magtibay P; Magrina J
J Minim Invasive Gynecol; 2017; 24(4):665-669. PubMed ID: 28254678
[TBL] [Abstract][Full Text] [Related]
16. Practice patterns and postoperative complications before and after US Food and Drug Administration safety communication on power morcellation.
Harris JA; Swenson CW; Uppal S; Kamdar N; Mahnert N; As-Sanie S; Morgan DM
Am J Obstet Gynecol; 2016 Jan; 214(1):98.e1-98.e13. PubMed ID: 26314519
[TBL] [Abstract][Full Text] [Related]
17. Uterine sarcomas and parasitic myomas after laparoscopic hysterectomy with power morcellation.
Tan-Kim J; Hartzell KA; Reinsch CS; O'Day CH; Kennedy JS; Menefee SA; Harrison TA
Am J Obstet Gynecol; 2015 May; 212(5):594.e1-10. PubMed ID: 25499259
[TBL] [Abstract][Full Text] [Related]
18. Uterine morcellation and survival in uterine sarcomas.
Bretthauer M; Goderstad JM; Løberg M; Emilsson L; Ye W; Adami HO; Kalager M
Eur J Cancer; 2018 Sep; 101():62-68. PubMed ID: 30025231
[TBL] [Abstract][Full Text] [Related]
19. Incidence of Malignancy and Myoma Variants at Surgery for Presumed Benign Symptomatic Myomas.
Damasco MR; Chan PK; Slonim M; Ang WC; Healey MG
J Minim Invasive Gynecol; 2017; 24(4):659-664. PubMed ID: 28216458
[TBL] [Abstract][Full Text] [Related]
20. Risk of unexpected uterine leiomyosarcoma during laparoscopic procedures: Experience from a single tertiary institute in Italy.
Surace A; Baù MG; Privitera S; Botta G; Danese S; Plazzotta C; Mitidieri M; Picardo E
Int J Gynaecol Obstet; 2022 Feb; 156(2):236-239. PubMed ID: 33834486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
